Phase I Study of Recombinant Human Interleukin 15 (rhIL-15) in Combination with Checkpoint Inhibitors Nivolumab and Ipilimumab in Subjects with Advanced Solid Tumours

Time: 2:05 pm
day: Day Two


  • Will discuss pre-clinical data and biological rationale for developing a clinical trial evaluating the combination of recombinant human interleuking-15 with immune checkpoint inhibitors
  • Discussion of preliminary safety data and clinical activity for the combination
  • Brief overview of the biomarker evaluation for this combination